Warning: The NCBI web site requires JavaScript to function. more...

PubMed

US National Library of Medicine National Institutes of Health

Create RSS
RSS Settings
- Search: Jansat JM[au]
- Number of items displayed:
- Feed name:
Create alert
Advanced
Help

Search results

Items: 21

Select item 318322031.

No evidence for interactions of dimethylfumarate (DMF) and its main metabolite monomethylfumarate (MMF) with human cytochrome P450 (CYP) enzymes and the P-glycoprotein (P-gp) drug transporter.

Aubets J, Jansat JM, Salva M, Birks VM, Cole RJ, Lewis J, Pitcher A, Hall M.

Pharmacol Res Perspect. 2019 Dec 2;7(6):e00540. doi: 10.1002/prp2.540. eCollection 2019 Dec.

PMID:: 31832203

Similar articles

Select item 225417452.

Pharmacokinetics and safety of aclidinium bromide in younger and elderly patients with chronic obstructive pulmonary disease.

de la Motte S, Beier J, Schmid K, Pascual S, Jansat JM, Gil EG.

Int J Clin Pharmacol Ther. 2012 Jun;50(6):403-12. doi: 10.5414/CP201628.

PMID:: 22541745

Similar articles

Select item 223661963.

Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers.

Lasseter K, Dilzer S, Jansat JM, Garcia Gil E, Caracta CF, Ortiz S.

Pulm Pharmacol Ther. 2012 Apr;25(2):193-9. doi: 10.1016/j.pupt.2012.02.002. Epub 2012 Feb 15.

PMID:: 22366196

Similar articles

Select item 222752724.

Mass balance and metabolism of aclidinium bromide following intravenous administration of [¹⁴C]-aclidinium bromide in healthy subjects.

Ortiz S, Flach S, Ho J, Li F, Caracta CF, Gil EG, Jansat JM.

Biopharm Drug Dispos. 2012 Jan;33(1):39-45. doi: 10.1002/bdd.1773. Epub 2012 Feb 27.

PMID:: 22275272

Similar articles

Select item 216286035.

Safety and tolerability of aclidinium administered intravenously and absolute bioavailability of inhaled aclidinium in healthy male participants.

Ortiz S, Flach S, Caracta C, Gil EG, Jansat JM.

J Clin Pharmacol. 2012 Jun;52(6):819-27. doi: 10.1177/0091270011406281. Epub 2011 May 31.

PMID:: 21628603

Similar articles

Select item 211946046.

Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: A phase I, open-label, single-dose clinical trial.

Schmid K, Pascual S, Gil EG, Ortiz S, Jansat JM.

Clin Ther. 2010 Sep;32(10):1798-812. doi: 10.1016/j.clinthera.2010.09.002.

PMID:: 21194604

Similar articles

Select item 205730817.

Activity of aclidinium bromide, a new long-acting muscarinic antagonist: a phase I study.

Schelfhout VJ, Ferrer P, Jansat JM, Peris F, Gil EG, Pauwels RA, Joos GF.

Br J Clin Pharmacol. 2010 May;69(5):458-64. doi: 10.1111/j.1365-2125.2010.03622.x.

PMID:: 20573081

Free PMC Article

Similar articles

Select item 200442428.

Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients.

Joos GF, Schelfhout VJ, Pauwels RA, Kanniess F, Magnussen H, Lamarca R, Jansat JM, Garcia Gil E.

Respir Med. 2010 Jun;104(6):865-72. doi: 10.1016/j.rmed.2009.12.003. Epub 2009 Dec 30.

PMID:: 20044242

Free Article

Similar articles

Select item 210830739.

Incurred sample reproducibility: views and recommendations by the European Bioanalysis Forum.

Timmerman P, Luedtke S, van Amsterdam P, Brudny-Kloeppel M, Lausecker B, Fischmann S, Globig S, Sennbro CJ, Jansat JM, Mulder H, Thomas E, Knutsson M, Kasel D, White SA, Kall MA, Mokrzycki-Issartel N, Freisleben A, Romero F, Andersen MP, Knebel N, de Zwart M, Laakso S, Hucker RS, Schmidt D, Gordon B, Abbott R, Boulanger P.

Bioanalysis. 2009 Sep;1(6):1049-56. doi: 10.4155/bio.09.108.